The size of the global schizophrenia drugs agents market was worth USD 6.96 billion in 2020 and is estimated to be growing at a CAGR of 2.4% to reach USD 7.84 billion by 2025.
MARKET DRIVERS:
Growing awareness of psychiatric illnesses, expanded medical treatments for the treatment of major mental disorders, a large and robust pipeline, increasing acceptance of innovative schizophrenia therapeutics in emerging markets, and a rise in the number of schizophrenia patients have all resulted in the growth of the schizophrenia drugs agents market.
China and India are expected to offer growth possibilities for the global market to expand further. The major driving factors for market growth are favorable healthcare reforms, a large aging population, increased health awareness, and a low-cost base. According to the World Health Organization, schizophrenia affected nearly 50 million people worldwide in 2013. Even though the prevalence of schizophrenia is declining, the rate of care and prescription for this condition is rising, indicating that there are future growth opportunities in schizophrenia treatment. Compared to mergers and acquisitions, the partnership created by collaborations and partnerships has a positive and immediate effect on growth. Furthermore, manufacturers of schizophrenia medications are concentrating their efforts on identifying new revenue streams. To do this, manufacturers are focusing on emerging markets as future growth areas.
MARKET RESTRAINTS:
High investment costs and a lack of knowledge, on the other hand, are limiting the market growth. The achievement of medication adherence is a big obstacle for the global market for schizophrenia drug agents.
The lack of sample-based tests is a big challenge preventing healthcare companies from designing new treatments for the schizophrenia drug market. It's difficult for researchers to investigate the root causes of schizophrenia because doctors can't take brain tissue samples from patients as they can in a biopsy on a cancer tumor anywhere in the body. Drug side effects such as drowsiness, insomnia, Dry mouth, and various other disorders are restraining the global schizophrenia drug market's development.
Impact of COVID-19 on the global schizophrenia drugs agents market:
COVID-19 pandemic impacted every market as same as the schizophrenia market. The COVID-19 pandemic outbreak is affecting the mental health population due to exposure to substantial psychosocial stress. An increment in vigilance for psychosis symptoms in patients with COVID-19 is warranted. The schizophrenia drug market should retain the linear progression in growth.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Therapeutic Class, Treatment and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on the global schizophrenia drugs agents market has been segmented and sub-segmented based on the therapeutic class, treatment, and region.
Schizophrenia Drugs Agents Market – By Therapeutic Class:
Based on therapeutic class, the second and third-generation anti-psychotics segments are the preferred treatment line for schizophrenia due to increased development in offering several advantages like improvement in treatment outcomes and decreased hospitalizations. The rise in the geriatric population and approvals for new products are the contributing factors in schizophrenia drugs.
Schizophrenia Drugs Agents Market – By Treatment:
Based on treatment, the injectable antipsychotics segment is holding a significant share in the schizophrenia treatment market. Long-acting injectable antipsychotics offer better efficiency and tolerability due to the improvement of adherence and more stable pharmacokinetics. Injectable antipsychotics will reduce risks of relapse in schizophrenia outpatients in combination with the quality of psychosocial.
Schizophrenia Drugs Agents Market – By Region:
Regionally, the Global Schizophrenia Drugs Agents market was dominated by North America, closely followed by Europe. Asia Pacific is expected to grow at a high CAGR.
North American region dominates the share due to rising demand for schizophrenia treatment, the increment of medical cases, and growth in the geriatric population. Moreover, many of the population is affected by schizophrenia. So, developing awareness among people and launching new drugs via rigorous clinical trials are growth factors for the schizophrenia drug market.
The second-largest share in the schizophrenia drug market is the European region. It also owns some profitable drivers, such as an increase in cases of mental health problems and an increase in the geriatric population. Expenditure of healthcare can also boost market growth due to adapting fast treatment and the latest drugs. In countries like Singapore, Hong Kong, and Japan, there is a high prevalence of mental health problems that can fuel market growth. As expected, the least share is contributing by the MEA region due to undeveloped infrastructure and lack of facilities for mental health problems. At present, every region is developing by establishing numerous hospitals.
PROMISING COMPANIES IN THE MARKET:
Some of the notable companies leading the global schizophrenia drugs agents market profiled in this report are Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan, and Pfizer.
KEY RECENT HAPPENINGS IN THIS MARKET:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutic class
5.1.1 Introduction
5.1.2 Second generation anti-psychotics
5.1.2.1 Risperdal
5.1.2.2 Invega
5.1.2.3 Zyprexa
5.1.2.4 Geodon
5.1.2.5 Seroquel
5.1.2.6 Latuda
5.1.2.7 Aristada
5.1.2.8 Fanapt
5.1.2.9 Saphris
5.1.2.10 Vraylar
5.1.3 Third generation anti-psychotics
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Therapeutic class
5.1.6 Market Attractiveness Analysis, By Therapeutic class
5.1.7 Market Share Analysis, By Therapeutic class
5.2 Treatment
5.2.1 Introduction
5.2.2 Oral anti-psychotics
5.2.3 Injectable anti-psychotics
5.2.4 Y-o-Y Growth Analysis, By Treatment
5.2.5 Market Attractiveness Analysis, By Treatment
5.2.6 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutic class
6.1.3.3 By Treatment
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutic class
6.1.4.3 By Treatment
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 Therapeutic class
6.1.5.3 By Treatment
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bristol-Myers Squibb
8.3 AstraZeneca
8.4 Sumitomo Dainippon
8.5 Eli Lilly
8.6 Alkermes
8.7 Vanda Pharma
8.8 Allergan
8.9 Pfizer
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
